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Novel psychoactive substances (NPS) – 
knowledge and expe riences of drug users from 
Hungary, Poland, the UK and the USA 
Background: The recent decade witnessed growing prevalence of novel psychoactive 
substances (NPS) among young people in Europe and elsewhere. The study, conducted in 
2011 as part of the EU-funded ReDNet project, aimed at better understanding of motives 
behind the demand for NPS among youth as well as at their information needs in this regard. In 
addition to historical values, the lessons learned during the legal status of NPS may contribute 
to a more general understanding of use of new drugs and to current drug policies. Method: 
A self-administered anonymous questionnaire on NPS was completed via internet among 
young people from Hungary, Poland, the United Kingdom and the United States (N=1353) 
when NPS in general still enjoyed legal status. Results: The majority of respondents (82%) used 
NPS in the last 12 months and approximately half of them experienced adverse eff ects from 
these substances. The most frequent motives behind NSP use were willingness to experiment 
with new substances. However, sense of security and confi dence in their composition as legal 
products were also important drivers of their consumption. Desired psychoactive eff ects and 
risks associated with their use were rated as the two most vital pieces of information to improve 
their knowledge about NPS. Conclusions: There were some diff erences between participants 
representing diff erent countries, however, the study also revealed many similarities, suggesting 
emergence of global youth consumption cultures, including NPS use. Provision of information 
on NPS, including their positive and negative eff ects, should play an important role in drug 
policies. Since the time of the study some qualities of NPS (such as confi dence in their 
composition as well as quality and sense of security) may have deteriorated after delegalisation. 
On the other hand, opinions of NPS users suggest that delegalisation may have a deterrent 
eff ect for one third of their consumers while would not aff ect majority of them. 
(Neuropsychopharmacol Hung 2019; 21(4): 152-163)
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INTRODUCTION 
Consumption of novel psychoactive substances (NPS) 
also known as “legal highs”, has become substantial 
problem for drug policy, public health and research 
(Corazza et al. 2013; European Monitoring Centre 
for Drugs and Drug Addiction, [EMCDDA], 2017 
A; Winstock & Wilkins, 2011). Th ese substances have 
been distributed as legal substitutes of illicit drugs 
such as cannabis, amphetamine, cocaine, ecstasy 
or LSD (Corazza et al. 2011; Measham et al., 2010; 
Schifano et al., 2011). Health consequences related 
to consumption of the “classic” or “old” illicit drugs 
have been well described in literature. In contrast, the 
psychoactive substances that have recently emerged 
are poorly understood in the scientifi c literature and 
their specifi c eff ects and toxicity are not known to the 
clinicians (Corazza et al., 2012; Patterson et al., 2017).
Novel psychoactive substances appear on the mar-
ket every week, have increasingly sophisticated forms, 
and can stay legal for longer. Initially, in response 
to the legal controls, new chemical structures were 
created, which might or might not present similar 
risks and remained legal until a new legislation 
was introduced to tackle them (Winstock & Wil-
kins, 2011). Th ose synthesising new substances and 
“cyber-entrepreneurs” distributing these substances 
over the internet used to be always a step ahead of 
the legislative eff orts to control them (Measham 
et al., 2010). High rates of their appearance on the 
market were well shown by the results of three 
projects: Psychonaut Web Mapping System I–II 
(www.psychonautproject.eu) (Deluca et al., 2012) 
and ReDNet (www.rednetproject.eu) funded by the 
European Commission, which identifi ed 650 new 
substances or their combinations (Corazza et al., 
2013). Since then, according to EMCDDA several 
dozen NPS were identifi ed every year, reaching a peak 
of approximately 100 in 2014 and 2015 (EMCDDA, 
2015; EMCDDA, 2016). However, in the following 
years the number has fallen - to 51 in 2017 and 55 
in 2018 (EMCDDA, 2018; EMCDDA, 2019). Th e 
causes of this fall are unclear, but may be the result of 
sustained eff orts undertaken in Europe to control NPS 
and legislative initiatives in China, where the majority 
of NPS is produced (EMCDDA, 2019). In order to end 
the cat and mouse game, several European countries, 
including Poland and the UK, introduced several legal 
solutions such as generic legislation that prohibits 
possession and supply of whole families of drugs with 
no requirement to assess the risk of using individual 
substances or blanket prohibition, according to 
which it is not allowed to produce, market, supply 
and posses substances with psychoactive properties, 
except those that have already been permitted, such 
as alcohol, tobacco, caff eine and registered medicines 
(Measham & Newcombe, 2017; Reuter & Pardo, 2016). 
It is worth adding that the pace at which changes 
were made in the legal regulations concerning NPS 
turned out to be a driving force in the development 
of new generations of NPS and retail innovations. For 
this reason, Fiona Measham and Russel Newcombe 
suggested that not “cat and mouse” but rather “hare 
and hounds” better describes the relationship between 
the NPS market and changes in the law (Measham & 
Newcombe, 2017). 
Th anks to the internet NPS are widely distributed 
as it off ers the ideal conditions for global trade, both 
through surface web as well as deep web, supported 
by technologies that allows to hide the identity of 
buyers and online vendors (EMCDDA, 2017 A). 
Th e internet facilitates direct contact between the 
customer and the seller, as well as receiving regular 
information about new products and forwarding 
this information to other people by e-mail or SMS. 
Against this backdrop, NPS and information on their 
eff ects are increasingly available to everyone. Novel 
psychoactive substances are traded via internet pages 
(Corazza et al., 2012; Corazza et al., 2013; EMCDDA, 
2017 A) and via network of specialized street shops as 
it happened in Poland several years ago (Dąbrowska 
& Bujalski, 2013). Despite restrictions introduced in 
most countries that used to have legal or semi-legal 
NPS trade, they can still be available in physical shops 
but more covertly (EMCDDA, 2019). As scientifi c 
knowledge of NPS is limited and needs immediate 
updates, the researchers in the fi eld have to utilise 
information and experiences on NPS collected and 
disseminated by their users (Corazza et al. 2011; 
Corazza et al. 2012; Corazza et al. 2013; Deluca et al., 
2012; Schifano et al., 2011).
THE REDNET PROJECT
Rapid increase of NPS supply and easy internet access 
call for novel preventive measure initiatives. One of 
these was the ReDNet project that was implemented 
by eight countries: Belgium, Germany, Hungary, Italy, 
Norway, Poland, Spain, the United Kingdom already 
eight years ago when NPS were still legal. Its main aim 
was to improve access to reliable information on NPS 
and the potential risks associated with their use. Th e 
project targeted users and professionals working with 
the young people using NPS (Corazza et al., 2013). 
Novel psychoactive substances (NPS)… O R I G I N A L  P A P E R
154 NEUROPSYCHOPHARMACOLOGIA HUNGARICA 2019. XXI. ÉVF. 4. SZÁM 
One of the components of ReDNet project was a 
survey among young NPS users conducted in Hungary, 
Italy, Poland, Spain and the United Kingdom. Th e aim 
of this survey was to address the following research 
questions: 1) What motives can be identifi ed behind 
reaching for new substances? 2) What information 
about new substances are regarded most useful for 
their users? 3) What are implications of legal status 
of new psychoactive substances?
Despite historical nature of the data, all these 
questions are relevant in a context of current drug 
policies and vibrant drug markets which still off er 
great variety of new substances.
METHODS
Sampling and data collection procedure
Th is paper is based on the self-report data taken in 
2011 from a sample of young drug users, who had 
experience with NPS. Th e respondents were recruited 
through the ReDNet project’s website and through in-
ternet forums, such as Bluelight, devoted to exchange 
of information and experiences on drugs, including 
NPS. Th e participants answered the self-administered 
questionnaire via the internet. Th ey were informed 
about the voluntary and anonymous nature of 
their involvement as well as purpose and practical 
value of the study. Th e questionnaire was available 
in English, Hungarian, Italian, Spanish and Polish. 
Preliminary analysis showed that among Italian and 
Spanish respondents, less than 10% confi rmed any 
experiences with NPS. Th erefore, these countries have 
not been included in further analysis. 
Initially, 2117 respondents were included. However, 
due to incomplete data or answers indicating 
that respondents did not take the study seriously 
(such as jokes and inconsistent responses), data 
of 25 participants were removed from the sample. 
Moreover, respondents who had no experience 
with NPS or refused to answer question on such 
substances use, were excluded (N=463; 22%). Th e 
English version of the questionnaire was addressed 
to the UK respondents. However, it was also fi lled 
in by a substantial number of persons from other 
English speaking countries, such as Australia, Canada, 
Ireland, and above all, the USA. Moreover, some 
questionnaires in English were fi lled in by single 
respondents from around the world – for example 
from: Argentina, Czech Republic, Chile, Denmark, 
Germany, Peru, Sweden, the Netherlands. Th ese 
participants (N=99) as well as Australian, Canadian 
and Irish (N=67) and those who did not answer the 
question on country of origin (N=110) were excluded 
from the analysis. Th e respondents from the USA 
will constitute a distinct group in further analyses in 
addition to the respondents from Hungary, Poland 
and the UK. 
Th us, our fi nal sample was 1353. Th e mean age was 
21.7 years (SD=4.52). Males constituted 87% of the 
respondents. 
Measures
Most of the measures used in the study were 
elaborated in English by the ReDNet team and 
subsequently translated into Hungarian and Polish. 
Th e questionnaire consisted of 27 questions related, 
among others to the following themes: 
· NPS and other drug use among respondents. First, 
the respondents were asked if they have heard of 
such “legal highs” as GBL, GHB, benzylpiperazine/
BZP, spice (JWH-018, herbal smoke), MDVP, me-
phedrone, salvia divinorum etc or knew someone 
who used them. All together the list consisted 
of names of 16 NPS. Th en the participants were 
to report their own experiences with NPS, key 
factors in onset of NPS as well as adverse eff ects 
related to NPS use. Th e questionnaire ended with 
a question about “classic” illegal drug use. 
· Importance of knowledge on NPS. Th ree items 
were related to importance of acquiring knowl-
edge on specifi c characteristics of NPS and pre-
ferred channels of information.
· Envisaged impact of delegalisation. A question 
“how would a change in the law would aff ect your 
use of legal highs?” was to explore opinions of NPS 
consumers if delegalisation would diminish their 
NPS use, make users to stop their use or have no 
impact whatsoever.
Demographic data
Demographic information, such as gender, age, em-
ployment and education were also requested. 
For all questions the respondents had the option to 
answer: “prefer not to say”.
Ethical issues
Th is research project was approved by the Bioethical 
Committee affi  liated to the Institute of Psychiatry 
and Neurology in Warsaw, Poland; the Institutional 
Review Board of the Faculty of Education and 
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Psychology, Eötvös Loránd University in Hungary; 
and King’s College London, UK - Psychiatry, Nursing 
& Midwifery Research Ethics Subcommittee (ref num 
PNM/10/11-85).
Statistical procedures
One Way ANOVA and chi-square was used to test 
the diff erences between countries.
RESULTS
Study population
As shown in a table 1 the biggest fraction of respondents 
(over 500) came from Poland while in three other 
countries the number of respondents varied between 
200 and 300. Men constituted 87% of the sample. In 
the UK, however, the proportion of women reached 
almost 17% comparing to no more than 11% in 
the remaining countries. Th ere was no signifi cant 
diff erence as regards to occupational status with over 
half of respondents in all countries being students, 
above a quarter employed, and approximately 12% 
unemployed or unable to work. One quarter of the 
study participants reported university education that 
ranged between 30% (Poland) and 14% (Hungary). 
Participants’ experiences related to NPS use 
In general, responders from diff erent countries were 
more similar than diff erent as regards to experiments 
with NPS (Table 2). Following the inclusion criteria, 
all participants used NPS at least once in their lifetime. 
Mean age of onset varied from 17.4 to 20.4 years. 
Most of them used NPS during the last 12 months, 
while approximately 50% of respondents used these 
substances frequently, i.e. during the last 30 days. NPS 
Table 1. Descriptive information on the study population
Descriptive information Frequency 
(%)
Hungary 
(N=296)
Poland 
(N= 552)
United Kingdom 
(N=207)
USA 
(N=298)
Total 
(N=1353)
Gender
Male 259 (87.5%) 480 (87.0%) 167 (80.7%) 264 (88.6%) 1170 (86.5%)
Female 31 (10.5%) 61 (11.1%) 35 (16.9%) 29 (9.7%) 156 (11.5%)
Other 1 (0.3%) 1 (0.2%) 1 (0.5%) 2 (0.7%) 5 (0.4%)
‘Prefer not to say’ or missing value 5 (1.7%) 10 (1.8%) 4 (1.9%) 3 (1.0%) 22 (1.6%)
Mean age 22.6 (SD=4.97) 22.4 (SD=4.46) 21.2 (SD=4.75) 19.8 (SD=3.29) 21.7 (SD=4.52)
Employment
Student 162 (54.7%) 268 (48.6%) 128 (61.8%) 172 (57.7%) 730 (54.0%)
Full-time job or part-time job 84 (28.4%) 170 (30.8%) 50 (24.2%) 76 (25.5%) 380 (28.1%)
Unemployed or unable to work 36 (12.2%) 63 (11.4%)  25 (12.1 %) 40 (13.4) 164 (12.1%)
‘Prefer not to say’ or missing value 14 (4.7%) 51 (9.2%) 4 (1.9%) 10 (3.4%) 79 (5.8%)
Education
University degree 42 (14.2%) 164 (29.7%) 57 (27.6%) 70 (23.5%) 333 (24.6%)
‘Prefer not to say’ or missing value 11 (3.7%) 30 (5.4%) 7 (3.4%) 60 (20.1%) 106 (8.0%)
Table 2. Substance use among respondents
Hungary 
(N=296)
Poland 
(N= 552)
United Kingdom 
(N=207)
USA 
(N=298)
Total 
(N=1353)
NPS use during the last 12 months 262 (92.3%) 365 (68.1%) 175 (86.6%) 274 (94.5%) 1076 (82.0%)
NPS use during the last 30 days 174 (60.4%) 200 (37.9%) 113 (56.2%) 183 (64.2%) 670 (51.5%)
Mean age of NPS use onset 20.5 (SD=4.92) 19.2 (SD=4.16) 17.7 (SD=4.09) 17.4 (SD=2.79) 18.8 (SD=4.22)
Illegal substance use 189 (71.6%) 445 (89.2%) 175 (88.8%) 255 (89.5%) 1074 (85.5%)
Missing values ranged from 2.4% to 10.8%
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use during the last 12 months and the last 30 days 
were less prevalent among participants from Poland 
than in the other countries and these diff erences 
were statistically signifi cant (p<0.001). Th ere was no 
statistical diff erence between Hungary and the USA. 
However, in comparison to respondents from the 
UK, signifi cantly more participants from Hungary 
(p<0.05) and the USA (p<0.01) used NPS during 
the last 12 months. Most of the study participants 
(85.5%) reported experiences with other illegal drugs 
with the exception of Hungary, where 72% had such 
experiences. 
Most of the NPS users (69%) highly rated their 
experiences with NPS (mean value on 5-point 
scale=4.07; SD=0.99) and only 30% were concerned 
about the long-term eff ects of NPS (data not 
presented in table). Respondents from the UK 
reported the highest satisfaction of NPS (M=4.26; 
SD=0.87), followed by respondents from the 
USA (M=3.94; SD=1.04), from Poland (M=3.74; 
SD=0.91), and eventually from Hungary (M=3.50; 
SD=1.03). Bonferroni post-hoc analysis showed that 
all diff erences between countries were statistically 
signifi cant. 
Despite these positive opinions, approximately half 
of the respondents experienced signifi cant negative 
reaction to NPS, though these negative reactions 
occurred less frequently among participants from 
the UK and the USA (35%-43%) compared to Poland 
and Hungary (63%-57%). Diff erences between the 
UK compared to the USA as well as between Hun-
gary compared to Poland were insignifi cant. Contact 
with health care system due to NPS use was endorsed 
by a minority (11%) of respondents while contact 
with specialised drug services about four percent. 
Th ere was no statistically signifi cant diff erences across 
countries (Table 3). 
Motives behind the NSP onset 
Th e most important factor in onset of NPS use was 
willingness to experience new drugs, followed by 
confi dence in product’s composition, easy access to NPS, 
good review from other people, aff ordability, legality 
and limited access to other drugs. Bonferroni post-hoc 
analysis indicated that for participants from the UK 
(as well as from the USA) willingness to experience 
new drugs was signifi cantly more important than for 
participants from Poland (mean diff erence=-0.41, 
p<0.001) and Hungary (mean diff erence=-1.27, 
p<0.001). For Hungarian respondents, confi dence in 
product and aff ordability were two most important 
factors, followed by easy access and legality. For 
Polish respondents, willingness to experience new 
drug was the primary factor followed by easy access, 
legality and confi dence in product’s composition. 
For respondents from the UK, besides willingness to 
experience new drug, most important factors were 
confi dence in product's composition, easy access and 
good review by other users. Finally, for participants 
from the USA the most important factors were 
willingness to experience a new drug, good review and 
aff ordability. Compared to the remaining countries 
low probability of being detected by urine tests 
was more important for participants from the USA 
(table 4). 
Th e beliefs that NPS are safer and less side-
eff ects generating than illicit drugs, as well as social 
acceptability of NPS and curiosity caused by media 
coverage were much less important factors for all 
Table 3. Negative consequences of NPS use 
Hungary 
(N=296)
Poland 
(N= 552)
United Kingdom 
(N=207)
USA 
(N=298)
Total 
(N=1353)
A signifi cant negative reaction to any 
NPS 161 (56.5%) 339 (63.1%) 70 (34.8%) 126 (43.4%) 696 (53.0%)
Contact with mental health services 
due to use of NPS 16 (5.6%) 49 (9.2%) 12 (6.1%) 21 (7.4%) 98 (7.5%)
Hospital/A&E attendance for reasons 
linked to use of NPS 17 (5.9%) 33 (6.1%) 18 (9.0%) 20 (6.9%) 88 (6.7%)
Contact with specialist drug 
treatment services due to use of NPS 13 (4.6%) 22 (4.1%) 6 (3.0%) 10 (3.5%) 51 (3.9%)
Any contact with health services due 
to NPS use 22 (8.0%) 65 (12.6%) 25 (13.0%) 30 (10.8%) 142 (11.2%)
Missing values ranged from 2.4% to 6.8%
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participants. No diff erences between countries were 
identifi ed in this regard (data on these factors are not 
presented in table). 
Information about NPS regarded as most useful 
for their users
Approximately half of our respondents were 
interested in receiving up-to-date information on 
NPS, however, the participants from the UK (47%) 
and the USA (45%) were less interested in receiving 
such information than respondents from Hungary 
(75%) and Poland (67%). Th e most preferred source 
of receiving up-to-date information were e-mail and 
websites (data not presented in table). 
Th e most important pieces of information about 
NPS characteristic were: desired psychoactive 
eff ect and risks of use. Table 5 reports results of 
one-way ANOVA. It was found that three kinds of 
information: overview/key points, modalities of 
use, appearance and price signifi cantly diff er by the 
country. Bonferroni post-hoc analysis indicated that 
the participants from Hungary perceived as more 
important overview (or key points) compared to the 
respondents from Poland (mean diff erence=0.23; 
p<0.01) and from the USA (mean diff erence=0.26; 
Table 4. Key factors in the onset of NPS 
Hungary 
(N=296)
Poland 
(N= 552)
United 
Kingdom 
(N=207)
USA 
(N=298)
Total 
(N=1353)
One Way 
ANOVA 
F
Mean value on 5-point scale 1 “not important” to 5 “very important”
Willingness to experience new drugs 2.96 3.83 4.24 4.22 3.79 59,60***
Confi dence in product’s composition 3.85 3.49 3.93 3.68 3.67 6.90***
Easy access – possibility to buy online 3.29 3.79 3.80 3.68 3.66 9.66***
Good “review” from other people 2.73 3.22 3.79 3.83 3.34 43.96***
Aff ordability 3.47 3.01 3.45 3.73 3.33 20.37***
Legality - no risk of police arrest 3.27 3.51 3.16 3.13 3.32 5.21***
Limited access to other drugs 2.58 3.19 3.00 3.19 3.03 11.26***
Better purity of NPS compared to illicit drugs 2.61 2.98 3.15 2.88 2.90 5.75***
Better high than illicit drugs 2.22 2.21 2.72 2.60 2.38 11.12***
Less easily detected by urine screens 2.10 2.31 1.84 3.18 2.38 40.38***
Less easily sniff ed by dogs 1.82 2.34 2.02 2.40 2.19 11.47***
*** p<0.001
Table 5. Demand for information. Importance of particular characteristics of NPS 
Mean value on 5-point scale (from 1 not important to 5 very important)
Hungary 
(N=296)
Poland 
(N= 552)
United 
Kingdom 
(N=207)
USA 
(N=298)
Total 
(N=1353)
One Way 
ANOVA 
F
Desired psychoactive eff ect 4.81 4.80 4.84 4.82 4.82 0.83
Risk of use 4.61 4.55 4.63 4.57 4.58 0.61
Overview/key points 4.65 4.42 4.44 4.38 4.46 5,24***
Modalities of use 4.03 4.15 4.28 4.26 4.17 3.00*
Price 3.49 3.72 3.44 3.44 3.56 4.48**
Appearance 3.73 3.17 3.36 3.39 3.37 10.68***
Marketing strategies 3.40 3.33 3.28 3.42 3.36 0.66
Legal status 3.37 3.18 3.13 3.35 3.25 1.67
*p<0.05; ** p<0.01; *** p<0.001
Novel psychoactive substances (NPS)… O R I G I N A L  P A P E R
158 NEUROPSYCHOPHARMACOLOGIA HUNGARICA 2019. XXI. ÉVF. 4. SZÁM 
p<0.01). Information on appearance of NPS was also 
more important for the Hungarian respondents than 
for participants from Poland (mean diff erence=0.56; 
p<0.001), the UK (mean diff erence=0.37, p<0.05) 
and the USA (mean diff erence=0.34; p<0.05). Th e 
participants from Poland perceived as more important 
information about price, especially in comparison to 
the respondents from the UK and the USA (mean 
diff erence =0.28; p<0.05). 
Implications of legal status
In all countries more than a half (58%) of the drug 
users claimed that a change in the law toward 
criminalization of NPS would not aff ect their NPS 
use, one fi ft h (22%) would use these substances 
less oft en while one in six would give up their use. 
Th e change of law seems to have no eff ect on two 
thirds of respondents from the UK and Hungary and 
approximately half of the participants form Poland 
and the USA. Diff erences in this regard between these 
two pairs of countries, i.e. Hungary + the UK and 
Poland + the USA are statistically signifi cant (p<0.01). 
Th e proportion of respondents who would stop NPS 
use in response to their delegalisation varied from 
5% in the UK to 15% in Hungary to almost 20% in 
Poland and the USA. In this case, respondents from 
the UK diff ered signifi cantly from participants from 
other countries (p<0.001) (table 6). 
DISCUSSION 
Experience with NPS
Th e study found more similarities than diff erences 
across participants from diff erent countries, which 
suggests they belong to an international NPS culture 
that has a few national specifi cities. Th e prevalence 
of using the "classic" drugs and NPS among our 
respondents from all participating countries was 
signifi cantly higher than in the case of the so-called 
"the general population”, traditionally covered by the 
epidemiological studies. Th e European School Survey 
Project on Alcohol and Other Drugs (ESPAD) study 
from 2015 shows that lifetime prevalence of NPS was 
about 4% (ranged from 1% to 10%) among 15-16 
year-olds, while the last year prevalence was about 
3% (Kraus et al., 2015). Similar results were obtained 
in the Eurobarometer 2015, which was conducted 
among 15-24 year-olds in the 28 European Union 
countries (Eurobarometer, 2015). It turned out that 
about 8% of young people in that age consumed NPS at 
least once in their lives, while the last year prevalence 
was about 3%. In 2011, when ReDNet project was 
conducted, the use of NPS was confi rmed by 5% of 
Eurobarometer respondents aged 15-24, including 
8% from the UK, 9% from Poland and only 2% from 
Hungary (Eurobarometer, 2011). In the ReDNet study 
the majority of respondents used NPS during the 
last at 12 months, which is obviously due to project 
recruitment strategy, i.e. via drug forums. However, 
Polish participants of the ReDNet study consumed 
NPS less frequently compared with Hungary, the UK 
and the USA. On the other hand, the participants 
from Poland as oft en as other respondents, especially 
from the UK and the USA, have confi rmed the use 
of the "classic" drugs.
About half of the respondents experienced a 
signifi cant negative reaction to NPS. Our results are 
corroborated by other studies conducted few years 
later. In a survey from 2016 among online community 
samples in 6 European countries, including Poland 
and Hungary, it was found that 51% of respondents 
had experienced acute unpleasant side eff ects 
aft er NPS use (Van Hout et al., 2018). In our study, 
participants from Hungary used NPS as oft en as 
Table 6. Envisaged impact of changing the law on NPS use 
Hungary 
(N=296)
Poland 
(N = 552) 
United Kingdom 
(N= 207)
USA 
(N=298)
Total 
(N= 1353)
I would use more 
often 8 (2.9%) 23 (4.4%) 4 (2.1%) 10 (3.5%) 45 (3.5%)
It would not aff ect 
my use 173 (63.4%) 288 (55.5%) 132 (68.4%) 147 (51.8%) 740 (58.3%)
I would use less 
often 50 (18.3%) 107 (20.6%) 47 (24.4%) 74 (26.1%) 278 (21.9%)
I would stop 42 (15.4%) 101 (19.5%) 10 (5.2%) 53 (18.7%) 206 (16.2%)
Missing values ranged from 4.7% to 7.8% 
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participants from the UK and the USA, but the highest 
percentage of Hungarian respondents (and Polish 
participants) has confi rmed a signifi cant negative 
reaction to any NPS. Th is result was refl ected in the 
data on the overall assessment of the NPS experience, 
which was the lowest in the case of the Hungarian 
respondents. Th ese results suggest that quality of NPS 
available on Hungary and Poland is lower compared 
to the UK and the US which are much more affl  uent 
and where consumers may demand better product 
and more comprehensive information. Drug markets 
seem not to be exception in this regard and depend 
on more general economic factors. Despite the fact 
that more than half of the respondents from Hungary 
had negative experiences with NPS, the prevalence 
of use of these substances in this group was high 
and did not diff er signifi cantly from the prevalence 
among participants in the UK and the USA, who less 
frequently reported negative reaction to NPS and gave 
relatively high rating of their experience with these 
substances. Th e ReDNet results indicate that negative 
experiences do not motivate NPS users to stop using 
drugs or to seek professional help. Moreover, our data 
showed substantially low level of treatment coverage 
as only few percent of respondents reported use of 
specialized drug treatment.
Motives behind reaching for new psychoactive 
substances
Th e highest rated motive to reach for NPS was the 
desire to experiment with new substances. Th is 
fi nding is supported by numerous studies that have 
shown that sensation seeking is an important factor 
when people engage in risky behaviors (Griffi  n et al., 
2003; Willoughby et al., 2007; Van Dorn et al., 2008). 
Moreover, other studies on NPS also showed that 
curiosity is the reason most frequently mentioned 
by NPS users (Sumnall et al., 2013, McLeod et al., 
2016; Soussan et al., 2018). Safety considerations, 
both health (better purity, less side eff ects) and legal 
(small possibility of detecting the presence of NPS 
in urine tests or by police dogs, and even the risk of 
arrest) were less important for our participants. A 
study conducted in Ireland also indicated that the 
possibility of being detected in drug screenings or by 
sniff er dogs does not seem to infl uence the decision to 
reach for these substances or not (Sumnall et al., 2013). 
Conversely, the study confi rms that the legality of 
NPS is an important motivating factor for using these 
substances (Measham et al., 2010; Measham, 2013; 
Sumnall et al., 2013; Soussan et al., 2018). However, 
legal status of NPS is more important for people who 
due to their occupation, being in drug treatment or 
contact with the criminal justice system can expect 
drug testing (Mesham & Newcombe, 2017). 
An important motive for using NPS was the 
confi dence in their composition. Th is was also found 
to be important in other studies (Sumnall et al., 2013; 
Soussan et al., 2018). It can be assumed that this 
certainty resulted from the legal or para-legal sta-
tus of these substances, which suggests that NPS are 
chemically tested as any other legal substances. Th us, 
legal status could have an impact on the dissemination 
of the use of new substances, providing consumers 
with a greater sense of security (Measham. 2013). 
Substantial quality deterioration of “classic” illicit 
substances combined with their growing prices was 
recognized as one of the reasons for the rapid growth 
of the supply of and demand for new substances 
(Measham et al., 2010; Measham, 2013). 
Since delegalisation of NPS in majority of countries 
in point, some advantages of their use may have 
disappeared as confi dence in their composition and 
quality. In fact, there are more and more reports about 
rapid deterioration of NPS quality and serious adverse 
events, such as overdose, deaths and infections 
associated with such substances use (EMCDDA, 
2017 B).
Th e study participants were interested in receiving 
up-to-date information on NPS provided via e-mail and 
websites. Unfortunately, as it is reported by EMCDDA, 
novel psychoactive substances appear on the market 
every week (EMCDDA, 2019). Gathering up reliable 
knowledge about the eff ects and consequences of using 
psychoactive substances takes time, so research of this 
issue has no chance to keep up with NPS manufacturers. 
In this situation, NPS consumers may be an important 
source of information for the researchers (Corazza 
et al. 2011; Corazza et al., 2012; Corazza et al., 2013; 
Deluca et al., 2012; Schifano et al., 2011). It should 
be remembered, however, that most NPS users do 
not know the actual composition and potency of 
substances they reach for (Patterson et al., 2017).
Th e possibility of buying NPS over the internet greatly 
facilitates access to these substances. Undoubtedly, 
as indicated by numerous studies, easy accessibility 
is an important risk factor for use of psychoactive 
substances (Measham et al., 2010, Measham, 2013; 
Measham & Newcombe, 2017). Moreover, the Inter-
net has become an important driver for the markets 
in general, including development of the NPS and 
drug markets, both directly through the sale of 
these substances via surface or deep web as well as 
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indirectly, because it allows manufacturers easy access 
to research and pharmaceutical data and creates 
forum to exchange information and experiences for 
potential users (EMCDDA, 2015). On the other hand, 
the novel digital interventions (‘apps’) are increasingly 
used to provide prevention and harm-reduction 
programs, treatment delivery as well as supervision 
and monitoring of patients (EMCDDA, 2019). Study 
conducted recently by EMCDDA showed, however, 
that only few of mobile or m-health apps have been 
evaluated, quality standard were lacking and there 
were concerns about the proper protection of personal 
data (EMCDDA, 2019).
Th e least important motive for our respondents was 
greater social acceptance for NPS, some of which had 
(or still has) the status of legal substances. However, 
this disregard of social acceptance is not surprising 
since NPS users, as well as users of "classic" illicit drugs, 
constitute a large part of those who challenge social 
norms and expectations (Donovan et al., 1991). 
Analysis of the diff erences between respondents 
from diff erent countries on motives showed that, 
contrary to the majority of the respondents, who 
were most interested in experimenting with the new 
substances, the Hungarian respondents rated as the 
fi rst choice their confi dence in NPS composition. On 
the other hand, the Hungarians less than the others 
assessed the importance of recommendation from 
other NPS users. Also, the issue of access to NPS via 
internet was far less important for the Hungarians 
than for the other respondents, in particular those 
from Poland and the USA. Moreover, the participants 
from Hungary signifi cantly underestimated the 
importance of such reasons for using NPS as limited 
access to other drugs. 
Th e study participants from Poland were much 
less likely than the other respondents to use NPS, 
while the highest percentage confi rmed a signifi cant 
negative reaction to them. Probably because of 
this, the respondents from Poland, similarly to the 
Hungarians estimated their experiences with NPS 
relatively lower. As in the case of the UK and the 
USA, in Poland the most important motive for 
reaching for NPS was the desire to experiment with 
new substances. On the other hand, the legal status 
of these substances and the resulting lack of risk of 
police arrest were considerably more signifi cant for 
Polish participants than for the other respondents.
Respondents from the UK, as opposed to Poles and 
Hungarians, paid much more attention to eff ects of 
NPS, which means that these substances produce 
better eff ects than "illicit drugs". Th e good reviews 
from other people were also of great importance to 
select particular NPS both for participants from the 
UK and the USA. 
In contrast, for respondents from the USA a more 
important factor was lower detectability, i.e. lesser 
risk to be detected by urine tests and by sniffi  ng dogs 
which is well understood considering the particularly 
repressive drug policy there.
In general, respondents from Hungary and Poland 
seem to be less satisfi ed and have more negative 
experiences with NPS compared with the remaining 
English speaking respondents. Th ey also rely less on 
the opinions of other NPS users. It could be related 
to the worse quality of NPS available as well as 
the participants’ lower linguistic competence. Th e 
latter may also be refl ected by their poorer access to 
information and higher information needs.
Th e most useful information about NPS, which 
the participants looked for, were the desired 
psychoactive eff ects and the adverse eff ects of using 
these substances. Respondents also expressed an in-
terest in the general description of the substances 
and their key characteristics including modalities of 
use. Information about price, appearance, marketing 
strategies, and legal status proved less relevant for 
participants. In other words, young people are looking 
for concise messages that will allow them to make an 
account of the possible benefi ts and possible losses 
associated with reaching for new substances – with 
health and safety risks rather than fi nancial losses 
appearing to be more important. Interestingly, there 
were not so many diff erences between respondents 
from diff erent countries in this regard suggesting 
emergence of global youth consumption culture which 
formulates similar demands and expectations.
Implications of legal status
Legal status of NPS off ers their consumers a sense 
of security not only in terms of lower risk of legal 
sanctions but also in terms of confi dence in the 
composition of the drug and its quality. 
However, our study confi rms general assumptions 
of contemporary drug policies that criminalisation 
of drugs have deterrent eff ect and discourages some 
people to use drugs. Despite majority who claims 
that delegalisation of NPS would not aff ect their 
consumption about one third would either reduce 
their consumption or would give up their use. It is 
also worth emphasizing that delegalization of NPS 
may have another eff ect because in response to 
legal sanctions manufacturers are introducing new 
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substances to the market. Taking into account that the 
most important motive for reaching for the NPS is the 
desire to experiment with new, previously unknown 
substances, the prohibition policy provides some of 
the users with new opportunities (Soussan et al., 2018).
Limitations of the study
No random sample of respondents was used as we 
aimed to recruit a relatively large group of NPS 
consumers, who are diffi  cult to reach. Th e majority of 
respondents were visitors to the online forums devoted 
to the exchange of information on new psychoactive 
substances. Th e prevalence of the use in this group, 
their knowledge and experience seem to be signifi cantly 
higher than among other teenagers and young adults. 
CONCLUSIONS
Novel psychoactive substance use is an important 
public health problem. Th is is indicated by the high 
percentage of respondents who have experienced the 
negative consequences of using NPS. In addition to 
legal measures, information should play an important 
role in drug policies towards NPS, which, on the one 
hand, may discourage some potential consumers and, 
on the other hand, reduce harm to those who use it. 
Users of the new substances are very diverse in terms 
of experience and knowledge of the psychoactive 
substances. Among them are those who look for 
new experiences and are very likely to take risks 
despite very extensive knowledge of the psychoactive 
substances. Information activities should take into 
account the specifi city of these recipients. On the 
other hand, the informational needs of young people 
are largely similar, regardless of their experience, 
and include the expected eff ects of these substances, 
particularly the side eff ects. Th e results of the study 
confi rm the initial assumptions of the ReDNet project, 
according to which the knowledge transfer of the new 
substances should be reliable, well documented and 
address both: reducing demand and reducing harm.
Moreover, the study which was completed in the 
‘golden period’ of NPS as legal compounds reminds us 
that their legal status increased a sense of security among 
their consumers including confi dence in their quality 
and composition which prevented some side-eff ects of 
their use. Aft er delegalisation, those advantages may 
have disappeared as their quality rapidly deteriorated 
and health and social risks increased.
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Új pszichoaktív szerek (ÚPSz) – magyarországi, 
lengyel, egyesült királyságbeli és amerikai drog-
használók tudása és tapasztalatai 
Háttér: Az elmúlt évtizedben az új pszichoaktív szerek (ÚPSz) növekvő előfordulását tapasztal-
hattuk Európában és azon kívül is. Jelen kutatás, mely 2011-ben készült az EU által támogatott 
ReDNet projekt keretében, az ÚPSz-ek használatának motivációt kívánta feltárni fi atalok köré-
ben, valamint az ezzel kapcsolatos információs szükségleteket. A történeti szempontok mellett 
az ÚPSz-ek jobb megértése a jogi környezet változása mellett hozzájárulhat a hatékonyabb 
drogpolitikák kialakításához is. Módszer: Magyar, lengyel, egyesült királyságbeli és amerikai 
(N = 1353) fi atalok töltöttek ki egy anonim, önkitöltős kérdőívet, online felületen, amikor az 
ÚPSz-ek még legálisak voltak. Eredmények: A válaszolók többsége (82%) az elmúlt hónap során 
használt ÚPSz-t és mintegy felük tapasztalt kellemetlen hatásokat a használattal kapcsolatosan. 
Az ÚPSz-ek használata mögötti leggyakoribb motiváció az új szerekkel való kísérletezésre való 
hajlam volt. Mindazonáltal a biztonságérzet és a szerekkel mint legális termékekkel kapcsolatos 
bizalom szintén fontos okok voltak a használat hátterében. A két legfontosabb információnak 
a szerekkel kapcsolatosan a vágyott pszichoaktív hatás és a használattal kapcsolatos kocká-
zatok megismerése volt. Következtetések: Az egyes országok között mutatkoztak bizonyos 
különbségek, bár jelentős hasonlóságok is, amelyek a használati kultúra jelentős globalizációját 
jelezték. Az eredmények alapján az ÚPSz-ekkel kapcsolatos információnyújtás, beleértve ezek 
pozitív és negatív hatásait, a hatékony drogpolitika része kell, hogy legyen. A kutatás elvégzése 
óta néhány megítélés (így például a legalitásuk okán a szerekbe vetett bizalom) változhatott 
a szerek legális státuszának megváltozása következtében. Másrészről, a használók véleményei 
alapján feltételezhetjük, hogy míg egyharmaduk esetében a legális státusz változásának lehet 
elrettentő hatása, addig a többségnél ez a hatás nem várható. 
Kulcsszavak: új pszichoaktív szerek, drogok, addikció, delegalizálás, nemzetközi vizsgálat
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